Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Mirati Therapeutics (MRTX)

Mirati Therapeutics (MRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,117,688
  • Shares Outstanding, K 70,148
  • Annual Sales, $ 12,440 K
  • Annual Income, $ -740,870 K
  • 60-Month Beta 0.77
  • Price/Sales 91.82
  • Price/Cash Flow N/A
  • Price/Book 3.63
Trade MRTX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -12.22
  • Most Recent Earnings $-2.49 on 11/06/23
  • Latest Earnings Date 02/27/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 7.00%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -2.61
  • Number of Estimates 7
  • High Estimate -2.24
  • Low Estimate -3.10
  • Prior Year -3.51
  • Growth Rate Est. (year over year) +25.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
58.54 +0.27%
on 01/22/24
59.46 -1.28%
on 01/12/24
-0.24 (-0.41%)
since 12/22/23
3-Month
55.14 +6.46%
on 10/27/23
59.46 -1.28%
on 01/12/24
+3.02 (+5.42%)
since 10/20/23
52-Week
27.30 +115.02%
on 08/08/23
64.41 -8.87%
on 10/06/23
+13.04 (+28.56%)
since 01/20/23

Most Recent Stories

More News
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END

ONCY : 1.0400 (+5.17%)
ONC.TO : 1.42 (+5.97%)
EXEL : 23.17 (+0.83%)
MRTX : 58.70 (-0.17%)
LLY : 762.66 (+1.13%)
PNT : 12.50 (+0.16%)
3 No-Brainer Stocks to Buy With $500 Right Now

A reasonably modest amount of money can go a long way when it's invested in time-tested businesses with sustained catalysts.

NEE : 60.17 (+0.15%)
NEP : 27.00 (-3.26%)
BMY : 51.59 (-1.43%)
MRTX : 58.70 (-0.17%)
MO : 44.51 (+1.46%)
Mirati: Q3 Earnings Snapshot

Mirati: Q3 Earnings Snapshot

MRTX : 58.70 (-0.17%)
The Fight Against Pancreatic Cancer Just Gained a New Ally with $200M VC Firm

VANCOUVER – USA News Group – A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent individuals and institutions such as MIT, Memorial...

AAPL : 173.72 (+0.64%)
NYT : 43.27 (-0.78%)
ONCY : 1.0400 (+5.17%)
ONC.TO : 1.42 (+5.97%)
MACK : 14.72 (-0.14%)
INCY : 57.34 (-1.76%)
MRTX : 58.70 (-0.17%)
BNTX : 92.99 (+0.55%)
3 Things About Bristol Myers Squibb That Smart Investors Know

The stock is down this year, but will its struggles fade into the rearview mirror?

BMY : 51.59 (-1.43%)
MRTX : 58.70 (-0.17%)
Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)

/PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced updated results from the KRYSTAL-7 Phase 2...

MRTX : 58.70 (-0.17%)
Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race

Major pharmaceutical companies are continuing to make substantial acquisitions in the field of oncology, sparking enthusiasm in the market. Bristol Myers Squibb (NYSE:BMY) just announced its plan to buy...

DTC.CN : 1.7200 (-1.71%)
BMY : 51.59 (-1.43%)
MRTX : 58.70 (-0.17%)
LLY : 762.66 (+1.13%)
PNT : 12.50 (+0.16%)
DTCFF : 1.3002 (-1.35%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CNSL, PCTI, SP, MRTX

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

CNSL : 4.30 (-0.23%)
PCTI : 6.99 (-0.14%)
SP : 51.72 (+0.04%)
MRTX : 58.70 (-0.17%)
Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race

Large pharmaceutical companies are increasingly investing in cancer treatment stocks, driven by the promise of medical breakthroughs and financial rewards. Eli Lilly became the latest Big Pharma giant...

DTC.CN : 1.7200 (-1.71%)
MGNX : 15.60 (-2.07%)
IOVA : 14.03 (+0.86%)
MRTX : 58.70 (-0.17%)
MRSN : 4.86 (-3.57%)
DTCFF : 1.3002 (-1.35%)
LLY : 762.66 (+1.13%)
PFE : 27.72 (-0.79%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NWLI, MRTX, SLGC, PNT

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

NWLI : 486.00 (+0.09%)
MRTX : 58.70 (-0.17%)
SLGC : 2.10 (-4.55%)
PNT : 12.50 (+0.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mirati Therapeutics, Inc. is a clinical-stage biotech developing kinase inhibitors and KRAS inhibitors.

See More

Key Turning Points

3rd Resistance Point 59.40
2nd Resistance Point 59.19
1st Resistance Point 58.95
Last Price 58.70
1st Support Level 58.50
2nd Support Level 58.29
3rd Support Level 58.05

See More

52-Week High 64.41
Last Price 58.70
Fibonacci 61.8% 50.23
Fibonacci 50% 45.86
Fibonacci 38.2% 41.48
52-Week Low 27.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar